Clinical trials with IDegLira Insulin naive patients In the DUAL-1 trial [19], 1663 insulin-naive patients with T2DM in use of metformin and/or pioglitazone were randomized to receive IDeglira, insulin degludec or liraglutide for 26 weeks
FATP5 promotor polymorphism (rs56225452), representing a putative gain-of-function mutation in the FATP5 promotor, correlated with BMI-dependent hepatic steatosis in males with biopsy proven NAFLD ( n = 103) [20], suggesting that genetic variation may underlie part of the contribution of FATP5 in NAFLD
Some other ways people can stay healthy and protect their bones while on GLP-1s include: (Lovelace, NBC News, 3/2
After six months of treatment, those with low LH had a much more normal hormonal profile, and 6/10 had restored menstrual cycles
Vitamin B 12 is a key element in methylation and has been shown to improve oxidative stress 2,4
The next step would be to prospectively study patients prescribed GLP-1 receptor agonists to confirm the associations we saw in this study, Nau told Healio
